Article Text

Download PDFPDF

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
  1. Lauren Lepone1,
  2. Renee Donahue1,
  3. Italia Grenga1,
  4. Caroline Jochems2,
  5. Kwong-Yok Tsang1,
  6. Simon Metenou1,
  7. Jacob Richards1,
  8. Christopher R Heery1,
  9. Ravi Madan3,
  10. James L Gulley4 and
  11. Jeffrey Schlom1
  1. Aff1 grid.417768.b0000000404839129Laboratory of Tumor Immunology and BiologyCenter for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda MD USA
  2. Aff2 grid.94365.3d0000000122975165National Cancer InstituteNational Institutes of Health Bethesda MD USA
  3. Aff3 grid.417768.b0000000404839129Genitourinary Malignancies BranchCenter for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda MD USA
  4. Aff4 grid.48336.3a0000000419368075Genitourinary Malignancies BranchNational Cancer Institute, National Institutes of Health Bethesda MD USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Several monoclonal antibodies (MAbs) with demonstrated clinical anti-cancer activities have been engineered as fully human IgG1 entities to also encompass their potential to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) of human tumor cells. Avelumab (MSB0010718C, EMD Serono, Pfizer) is a fully human IgG1 MAb targeting the co-regulatory protein Programmed Death-Ligand 1 (PD-L1), and is thus distinct from other MAbs targeting the PD-L1/PD-1 axis currently being evaluated in clinical trials. Concern has been raised that an anti-PD-L1 antibody capable of inducing ADCC may negatively affect PD-L1 expressing immune cell subtypes. This work is intended to determine if there is any validity to this concern.


The clinical activity of Avelumab, observed in several tumor types in ongoing clinical studies such as NCT01772004, has been and will be reported elsewhere. In the studies reported here, Avelumab is shown to mediate ADCC of several types of human tumor cell lines (e.g., breast, lung, bladder carcinomas) in vitro, with tumor cell lysis mediated mainly by human CD16+ monocytes and natural killer (NK) cells. Since some human immune cell subsets express PD-L1 on their surface, studies were undertaken to evaluate changes in the frequency of immune cell subsets in peripheral blood mononuclear cells (PBMC) from cancer patients pre- vs post-treatment with Avelumab. Immune cells evaluated were PD-L1 positive and PD-L1 negative subsets of the following: CD4+ T cells, CD8+ T cells, NK cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSC), natural killer T cells (NKT), plasmacytoid dendritic cells (DC), conventional DC, and B cells.


Forty-two post-treatment PBMC samples were evaluated as follows: pre vs 1 dose of Avelumab (day 15, n = 19); pre vs 3 doses of Avelumab (day 43, n = 14); and pre vs 9 doses of Avelumab (day 127, n = 16). In all cases there were no statistical differences pre- vs post-treatment in any immune cell subset, and at any time point analyzed, regardless of whether the immune subset expressed PD-L1 or not. In addition, no changes were observed in absolute lymphocyte counts at any time point analyzed. Statistical analysis of all relevant immune cell subsets will be presented.


While immune cell subsets pre- vs post-treatment continue to be analyzed in various patient cohorts, these studies provide evidence that Avelumab, a fully human IgG1 MAb, capable of mediating ADCC, can be administered safely to cancer patients without altering the balance of numerous PBMC immune cell subsets.